Summary of findings 4. 6‐Mercaptopurine versus methotrexate for maintenance of remission in ulcerative colitis.
| 6‐Mercaptopurine versus methotrexate for maintenance of remission in ulcerative colitis | ||||||
| Patient or population: Patients with quiescent ulcerative colitis Settings: Outpatients Intervention: 6‐Mercaptopurine versus methotrexate | ||||||
| Outcomes | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | No of Participants (studies) | Quality of the evidence (GRADE) | Comments | |
| Assumed risk | Corresponding risk | |||||
| Control | 6‐MP versus MTX | |||||
| Failure to maintain remission | 917 per 10001 | 504 per 1000 (284 to 871) | RR 0.55 (0.31 to 0.95) | 26 (1 study) | ⊕⊕⊝⊝ very low2,3 | |
| *The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio; 6‐MP: 6 mercaptopurine; MTX: methotrexate | ||||||
| GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate. | ||||||
1 Control group risk estimates come from control arm of included study. 2 Downgraded one level due to high risk of bias (open label design). 3 Downgraded two levels due to very sparse data (18 events).